252 related articles for article (PubMed ID: 15775689)
1. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Saba N; Khuri F
Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Joshi AD; Carter JA; Botteman MF; Kaura S
Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
[TBL] [Abstract][Full Text] [Related]
3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
4. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Saba N; Khuri F
Oncology; 2005; 68(1):10-7. PubMed ID: 15775688
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
6. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
9. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Hirsh V
Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in lung cancer: more than a palliative therapy?
Jahanzeb M; Hirsh V
Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
[TBL] [Abstract][Full Text] [Related]
12. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Mahtani R; Khan R; Jahanzeb M
Clin Lung Cancer; 2011 Jan; 12(1):26-32. PubMed ID: 21273176
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Rosen LS
Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
15. Metastatic bone disease and tumour-induced hypercalcaemia: treatment options.
Heatley S
Int J Palliat Nurs; 2004 Jan; 10(1):41-6. PubMed ID: 14966444
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Diel IJ; Solomayer EF; Bastert G
Clin Breast Cancer; 2000 Apr; 1(1):43-51. PubMed ID: 11899389
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Major PP; Cook R
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]